Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group.

Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19.

PMID:
26494524
2.

PDE3A mutations cause autosomal dominant hypertension with brachydactyly.

Maass PG, Aydin A, Luft FC, Schächterle C, Weise A, Stricker S, Lindschau C, Vaegler M, Qadri F, Toka HR, Schulz H, Krawitz PM, Parkhomchuk D, Hecht J, Hollfinger I, Wefeld-Neuenfeld Y, Bartels-Klein E, Mühl A, Kann M, Schuster H, Chitayat D, Bialer MG, Wienker TF, Ott J, Rittscher K, Liehr T, Jordan J, Plessis G, Tank J, Mai K, Naraghi R, Hodge R, Hopp M, Hattenbach LO, Busjahn A, Rauch A, Vandeput F, Gong M, Rüschendorf F, Hübner N, Haller H, Mundlos S, Bilginturan N, Movsesian MA, Klussmann E, Toka O, Bähring S.

Nat Genet. 2015 Jun;47(6):647-53. doi: 10.1038/ng.3302. Epub 2015 May 11.

PMID:
25961942
3.

Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.

Blagden M, Hafer J, Duerr H, Hopp M, Bosse B.

Neurogastroenterol Motil. 2014 Dec;26(12):1792-801. doi: 10.1111/nmo.12463. Epub 2014 Oct 23.

4.

Hair for brain trade-off, a metabolic bypass for encephalization.

Dror Y, Hopp M.

Springerplus. 2014 Sep 27;3:562. doi: 10.1186/2193-1801-3-562. eCollection 2014.

5.

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.

Ahmedzai SH, Leppert W, Janecki M, Pakosz A, Lomax M, Duerr H, Hopp M.

Support Care Cancer. 2015 Mar;23(3):823-30. doi: 10.1007/s00520-014-2435-5. Epub 2014 Sep 14.

6.

Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.

Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, Oksche A, Reimer K, Winkelmann J, Allen RP, Kohnen R; RELOXYN Study Group.

Lancet Neurol. 2013 Dec;12(12):1141-50. doi: 10.1016/S1474-4422(13)70239-4. Epub 2013 Oct 18. Erratum in: Lancet Neurol. 2013 Dec;12(12):1133.

PMID:
24140442
7.

Low absolute bioavailability of oral naloxone in healthy subjects.

Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Bell D.

Int J Clin Pharmacol Ther. 2012 May;50(5):360-7.

PMID:
22541841
8.
9.

Cardiac disease in methylmalonic acidemia.

Prada CE, Al Jasmi F, Kirk EP, Hopp M, Jones O, Leslie ND, Burrow TA.

J Pediatr. 2011 Nov;159(5):862-4. doi: 10.1016/j.jpeds.2011.06.005. Epub 2011 Jul 23.

PMID:
21784454
10.

Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers.

Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Palaniappan K, Church A, Limb M, Connor A.

Expert Opin Investig Drugs. 2011 Apr;20(4):427-39. doi: 10.1517/13543784.2011.563236.

PMID:
21395483
11.

Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries.

Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M.

Curr Med Res Opin. 2011 Jan;27(1):35-44. doi: 10.1185/03007995.2010.535270. Epub 2010 Nov 18.

PMID:
21083515
12.
13.

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevcik P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K.

Int J Clin Pract. 2010 May;64(6):763-74. doi: 10.1111/j.1742-1241.2010.02360.x. Epub 2010 Mar 29.

14.

Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management.

Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, Spohr I, Reimer K.

J Opioid Manag. 2009 May-Jun;5(3):145-51. Review.

PMID:
19662924
15.

Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.

Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K.

Expert Opin Pharmacother. 2009 Mar;10(4):531-43. doi: 10.1517/14656560902796798 .

PMID:
19243306
16.

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K.

Clin Ther. 2008 Nov;30(11):2051-68. doi: 10.1016/j.clinthera.2008.11.008.

PMID:
19108793
17.

Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.

Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K.

Curr Med Res Opin. 2008 Dec;24(12):3503-12. doi: 10.1185/03007990802584454 .

PMID:
19032132
18.

Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach.

Reimer K, Hopp M, Zenz M, Maier C, Holzer P, Mikus G, Bosse B, Smith K, Buschmann-Kramm C, Leyendecker P.

Pharmacology. 2009;83(1):10-7. doi: 10.1159/000165778. Epub 2008 Oct 28. Review.

PMID:
18957874
19.

A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.

Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K.

Eur J Pain. 2009 Jan;13(1):56-64. doi: 10.1016/j.ejpain.2008.06.012. Epub 2008 Aug 31.

PMID:
18762438
20.

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.

Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, Ruckes C, Weber S, Grothe B, Fleischer W, Reimer K.

J Pain. 2008 Dec;9(12):1144-54. doi: 10.1016/j.jpain.2008.06.014. Epub 2008 Aug 16.

PMID:
18708300
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk